These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 36866390)
1. Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis. Gairing SJ; Danneberg S; Kaps L; Nagel M; Schleicher EM; Quack C; Engel S; Bittner S; Galle PR; Schattenberg JM; Wörns MA; Luessi F; Marquardt JU; Labenz C JHEP Rep; 2023 Apr; 5(4):100671. PubMed ID: 36866390 [TBL] [Abstract][Full Text] [Related]
2. Animal naming test is a simple and valid tool for detecting covert hepatic encephalopathy and predicting outcomes in Chinese-speaking regions: a preliminary study. Huang CH; Yu TY; Tseng WJ; Huang YT; Chang SH; Hsieh SY; Chien RN; Amodio P Ann Med; 2023 Dec; 55(1):2236013. PubMed ID: 37494454 [TBL] [Abstract][Full Text] [Related]
3. Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score. Patel AV; Wade JB; Thacker LR; Sterling RK; Siddiqui MS; Stravitz RT; Sanyal AJ; Luketic V; Puri P; Fuchs M; Matherly S; White MB; Unser A; Heuman DM; Bajaj JS Clin Gastroenterol Hepatol; 2015 May; 13(5):987-91. PubMed ID: 25445772 [TBL] [Abstract][Full Text] [Related]
4. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis. Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457 [TBL] [Abstract][Full Text] [Related]
5. Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. Miwa T; Hanai T; Nishimura K; Maeda T; Ogiso Y; Imai K; Suetsugu A; Takai K; Shiraki M; Shimizu M JPEN J Parenter Enteral Nutr; 2022 May; 46(4):858-866. PubMed ID: 34287991 [TBL] [Abstract][Full Text] [Related]
6. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446 [TBL] [Abstract][Full Text] [Related]
7. Covert hepatic encephalopathy is associated with aggressive disease progression and poor survival in patients with cirrhosis. Wang J; Deng MJ; Shi PM; Peng Y; Wang XH; Tan W; Wang PQ; Chen YX; Yuan ZL; Ning BF; Xie WF; Yin C J Dig Dis; 2023 Dec; 24(12):681-690. PubMed ID: 38108656 [TBL] [Abstract][Full Text] [Related]
8. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578 [TBL] [Abstract][Full Text] [Related]
9. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852 [TBL] [Abstract][Full Text] [Related]
10. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study. Miwa T; Hanai T; Hirata S; Nishimura K; Sahashi Y; Unome S; Imai K; Shirakami Y; Suetsugu A; Takai K; Shimizu M Clin Nutr ESPEN; 2024 Oct; 63():267-273. PubMed ID: 38972037 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study. Rathi S; Chopra M; Chouduri G; Sharma P; Madan K; Chhabra M; Rai RR; Govil A; Konar A; Goenka M; Agarwal M; Mukherjee J; Thorat V; Salunkhe S; Abraham P; Nagral A; Jhaveri A; Bhat N; Varghese J; R S A; Ravishankar ; Reddy DC; Dhiman RK J Clin Exp Hepatol; 2019; 9(4):476-483. PubMed ID: 31516264 [TBL] [Abstract][Full Text] [Related]
13. Urinary metabolic profiling by McPhail MJ; Montagnese S; Villanova M; El Hadi H; Amodio P; Crossey MM; Williams R; Cox IJ; Taylor-Robinson SD Metab Brain Dis; 2017 Apr; 32(2):331-341. PubMed ID: 27638475 [TBL] [Abstract][Full Text] [Related]
14. Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Greinert R; Zipprich A; Simón-Talero M; Stangl F; Ludwig C; Wienke A; Praktiknjo M; Höhne K; Trebicka J; Genescà J; Ripoll C Liver Int; 2020 Dec; 40(12):3093-3102. PubMed ID: 32890428 [TBL] [Abstract][Full Text] [Related]
15. Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. Labenz C; Toenges G; Schattenberg JM; Nagel M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA Clin Transl Gastroenterol; 2020 Jun; 11(6):e00172. PubMed ID: 32568474 [TBL] [Abstract][Full Text] [Related]
16. Serum glial fibrillary acidic protein is sensitive to acute but not chronic tissue damage in cerebral small vessel disease. Gattringer T; Enzinger C; Pinter D; Fandler-Höfler S; Kneihsl M; Haidegger M; Eppinger S; Demjaha R; Buchmann A; Jerkovic A; Schmidt R; Khalil M J Neurol; 2023 Jan; 270(1):320-327. PubMed ID: 36056929 [TBL] [Abstract][Full Text] [Related]
17. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341 [TBL] [Abstract][Full Text] [Related]
18. Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis. Soma N; Uchida Y; Kouyama JI; Naiki K; Usui N; Sato A; Yamada S; Tsuji S; Ando S; Sugawara K; Nakao M; Nakayama N; Imai Y; Tomiya T; Mizuno S; Mochida S J Gastroenterol; 2024 Oct; ():. PubMed ID: 39412575 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. Bale A; Pai CG; Shetty S; Balaraju G; Shetty A J Clin Exp Hepatol; 2018 Jun; 8(2):156-161. PubMed ID: 29892178 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. Duarte-Rojo A; Allampati S; Thacker LR; Flud CR; Patidar KR; White MB; Klair JS; Heuman DM; Wade JB; Gavis EA; Bajaj JS Metab Brain Dis; 2019 Feb; 34(1):289-295. PubMed ID: 30506333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]